# Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor

> **NCT02007629** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 61 (actual)

## Conditions studied

- Hypertension, Pulmonary

## Interventions

- **DRUG:** Riociguat (Adempas, BAY63-2521)

## Key facts

- **NCT ID:** NCT02007629
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-18
- **Primary completion:** 2016-12-29
- **Final completion:** 2016-12-29
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2019-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02007629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02007629, "Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02007629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*